drugset
drugset / Trial / NCT04932005

A Study of DZD2269 in Healthy Adult Participants

NCT04932005 ↗

Phase 1 Completed 72 enrolled Dizal Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a research study in healthy participants. The purpose of this study is to see how safe the study drug is and how well it is tolerated after dosing. This study will also investigate pharmacokinetics of DZD2269; renal excretion of DZD2269 will also be evaluated. The study will also measure biomarkers such as pCREB in the blood.

Timeline

Start
2021-06-29
Primary completion
2022-04-01
Completion
2022-04-12

Drugs

EvaluationDrugModalityDoseRoute
Subject DZD2269 Unknown 5 mg Oral
Subject DZD2269 Unknown 10 mg Oral
Subject DZD2269 Unknown 20 mg Oral
Subject DZD2269 Unknown 30 mg Oral
Subject DZD2269 Unknown 40 mg Oral
Subject DZD2269 Unknown 80 mg Oral
Subject DZD2269 Unknown 160 mg Oral

Indications

No indication recorded.